Riyadh, Saudi Arabia- May, 2024- Bayer and Huma Therapeutics Limited announced the launch of their innovative heart health screening tool in Saudi Arabia. This marks the first global launch since the Bayer Aspirin Heart Health Risk Assessment went live in the US in 2023, and is aimed at supporting key objectives of the Vision 2030 national strategy for Saudi Arabia.
The Bayer Aspirin Heart Health Risk Assessment is a digital-only tool that rapidly evaluates an individual’s risk for developing cardiovascular disease (CVD) over the next decade, without the need for invasive blood tests and blood pressure measurement. Huma developed the algorithm by leveraging 15+ years of longitudinal data from over 500,000 individuals from the UK Biobank Dataset. Clinical validation of the algorithm in the European Society of Cardiology found that the Heart Health Risk Assessment had very good predictive ability when compared to the standard of care.
Dan Vahdat, CEO and Founder of Huma, said: “We are proud to be supporting heart health at scale with the launch of the Heart Health Risk Assessment and we look forward to further collaborations with the Ministry of Health as part of our commitment to fostering a healthier future for the people of Saudi Arabia.”
Also Read: Bayer and Aignostics to collaborate on next-generation precision oncology
Mohamed Galal, Vice President of Middle East and Pakistan at Bayer said: “Our partnership with Huma to expand the Heart Health Risk Assessment tool to Saudi Arabia underscores our commitment to leveraging digital health solutions for preventive care.”
Maged ElShazly, Bayer’s Managing Director & Country Commercial Lead Consumer Health in Saudi Arabia, commented on the partnership expansion, “Our collaboration with Huma is a testament to Bayer’s commitment to advancing digital health solutions that can make a real difference in people’s lives. The launch of the Heart Health Risk Assessment tool in Saudi Arabia is a significant step towards achieving the goals of the Vision 2030 strategy.”
Beyond Saudi Arabia, Bayer and Huma plan to bring the Heart Health Risk Assessment to Latin America in the coming year.
